About: http://data.cimple.eu/news-article/642f67f9e3016eeab262a24d7cc77809d07286cc2dd8be1f0e2451ba

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/642f67f9e3016eeab262a24d7cc77809d07286cc2dd8be1f0e2451ba Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America's top infectious diseases expert said the study showed the medication has "clear-cut" benefits. Complete results from the research, which was carried out by US government agency the National Institute of Allergy and Infectious Diseases (NIAID), were published by leading medical periodical the New England Journal of Medicine. The United States authorized the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suit. The study found that remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalized COVID-19 patients compared to a placebo in clinical tests on just over a thousand patients across 10 countries. On April 29, NIAID director Anthony Fauci, who has become the US government's trusted face on the coronavirus pandemic, said preliminary evidence indicated remdesivir had a "clear-cut, significant and positive effect in diminishing the time to recovery." The National Institutes of Health, of which the NIAID is a part, said Friday in a statement online that investigators found "remdesivir was most beneficial for hospitalized patients with severe disease who required supplemental oxygen." But the authors of the trial wrote that the drug did not prevent all deaths. "Given high mortality despite the use of remdesivir, it is clear that treatment with an anti-viral drug alone is not likely to be sufficient," they said. About 7.1 percent of patients given remdesivir in the trial group died within 14 days -- compared with 11.9 percent in the placebo group. However, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drug. ioco/roc/rbu/axn
schema:headline	Anti-viral drug effective against coronavirus, study finds
schema:mentions	Oxygen therapy Intravenous therapy New England Antiviral drug Placebo Remdesivir National Institute of Allergy and Infectious Diseases Mortality rate Allergy Europe Anthony S. Fauci Japan Pandemic United States Severe acute respiratory syndrome coronavirus 2 Roc (mythology) AXN
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-05-23 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	88 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness
http://data.cimple...romotesConspiracy	suppressed cures conspiracy theory

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software